Keeping the patient at the center is just as important in the development of high-risk innovations that serve unmet needs as it is for all other medtech solutions. That is the view of Pixium Vision CEO Khalid Ishaque, whose company is on the cusp of taking many dry-AMD sufferers out of blindness with artificial bionic vision technology. It recently performed the first successful human implantation and activation of its Prima implant.
For innovators like Pixium Vision, which is developing a second-generation bionic vision restoration system, there are many bases to cover as the technology is shepherded through development, into trials, and some years later, into reimbursed use.
Positive news flow is a vital component for future funding, confidence building and convincing clinicians, so the French Euronext-listed company...